[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA26861A1 - Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires - Google Patents

Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires

Info

Publication number
MA26861A1
MA26861A1 MA26709A MA26709A MA26861A1 MA 26861 A1 MA26861 A1 MA 26861A1 MA 26709 A MA26709 A MA 26709A MA 26709 A MA26709 A MA 26709A MA 26861 A1 MA26861 A1 MA 26861A1
Authority
MA
Morocco
Prior art keywords
vla
treatment
inflammatory
autoimmune
cell binding
Prior art date
Application number
MA26709A
Other languages
English (en)
Inventor
Stanley Chupak Louis
Jacob Duplantier Allen
John Milici Anthony
Fang Lau Wan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26861A1 publication Critical patent/MA26861A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 28 Décembre 1999 60/173,260 Voir en annexe le titre de l'invention et le texte de l'abrégé Inhibiteurs non peptidiques de la liaison cellulaire sous la dépendance de VLA-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires Il est décrit un groupe de composés non I peptidiques, dans lequel lesdits composés sont des inhibiteurs de VLA-4 utiles dans le traitement de maladies inflammatoires, auto-immunes et respiratoires, et dans lequel lesdits composés comprennent un composé de formule (1.0.0) et ses sels pharmaceutiquement acceptables ainsi que ses autres dérivés consistant en précurseurs médicamenteux.
MA26709A 1999-12-28 2002-06-24 Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires MA26861A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17326099P 1999-12-28 1999-12-28

Publications (1)

Publication Number Publication Date
MA26861A1 true MA26861A1 (fr) 2004-12-20

Family

ID=22631221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26709A MA26861A1 (fr) 1999-12-28 2002-06-24 Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires

Country Status (35)

Country Link
US (4) US20020049236A1 (fr)
EP (1) EP1244656A1 (fr)
JP (1) JP2003519697A (fr)
KR (1) KR20020067050A (fr)
CN (1) CN1413210A (fr)
AP (1) AP2002002565A0 (fr)
AR (1) AR029216A1 (fr)
AU (1) AU2018301A (fr)
BG (1) BG106867A (fr)
BR (1) BR0016818A (fr)
CA (1) CA2396087A1 (fr)
CO (1) CO5261616A1 (fr)
CR (1) CR6682A (fr)
CZ (1) CZ20022072A3 (fr)
EA (1) EA004673B1 (fr)
EE (1) EE200200372A (fr)
GT (1) GT200000226A (fr)
HU (1) HUP0203897A3 (fr)
IL (1) IL149758A0 (fr)
IS (1) IS6382A (fr)
MA (1) MA26861A1 (fr)
NO (1) NO20023085L (fr)
NZ (1) NZ518886A (fr)
OA (1) OA12126A (fr)
PA (1) PA8509301A1 (fr)
PE (1) PE20010987A1 (fr)
PL (1) PL357109A1 (fr)
SK (1) SK8692002A3 (fr)
SV (1) SV2002000246A (fr)
TN (1) TNSN00256A1 (fr)
TR (1) TR200201668T2 (fr)
UY (1) UY26512A1 (fr)
WO (1) WO2001051487A1 (fr)
YU (1) YU41202A (fr)
ZA (1) ZA200205142B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051487A1 (fr) * 1999-12-28 2001-07-19 Pfizer Products Inc. Inhibiteurs non peptidyle de liaison cellulaire dependant de vla-4 utiles pour le traitement de maladies inflammatoires, auto-immunes et respiratoires
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
TWI312779B (fr) 2000-12-28 2009-08-01 Daiichi Seiyaku Co
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
EP1650205B1 (fr) 2003-07-24 2012-04-25 Daiichi Sankyo Company, Limited Compose acide cyclohexanecarboxylique
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
US20050209232A1 (en) * 2004-02-10 2005-09-22 Kent Barbay Pyridazinone ureas as antagonists of alpha4 integrins
WO2005077915A1 (fr) * 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinones en tant qu'antagonistes d'intégrines $g(a)4
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
CA2583267A1 (fr) * 2004-10-12 2006-04-27 Amgen Inc. Nouveaux antagonistes des recepteurs de la bradykinine b1
WO2006133045A1 (fr) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Préparations de benidipine nanoparticulaire
US8987306B2 (en) * 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
WO2006133338A1 (fr) * 2005-06-07 2006-12-14 The Trustees Of The University Of Pennesylvania Inhibiteurs d'integrine a2b1/gpia-iia
US8129366B2 (en) 2005-12-13 2012-03-06 Daiichi Sankyo Company, Limited VLA-4 inhibitory drug
US7723345B2 (en) 2005-12-29 2010-05-25 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
CA2714335A1 (fr) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methodes de traitement de la sclerose en plaques par administration d'une alpha-foetoproteine combinee a un antagoniste de l'integrine
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010059315A1 (fr) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Lieurs de sérum-albumine humaine et conjugués de ceux-ci
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
WO2012061074A1 (fr) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. Procédés de détermination de différences dans l'activité alpha-4 intégrine par la corrélation de différences des taux de svcam et/ou de smadcam
JP5971657B2 (ja) * 2011-04-20 2016-08-17 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
CN103906733A (zh) 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
CN102268067A (zh) * 2011-06-29 2011-12-07 河北师范大学 一种含ldv序列短肽的聚乙二醇化衍生物
BR112014009310A2 (pt) 2011-10-17 2017-04-11 Westfaelische Wilhelms-Universitaet Muenster métodos de avaliação de riscos de lmp e aparelhos relacionados
CA2857344C (fr) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Agents antiviraux de l'hepatite b
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
SG11201501362PA (en) 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP2961732B1 (fr) 2013-02-28 2017-04-12 Janssen Sciences Ireland UC Sulfamoyl-arylamides comme médicaments pour le traitement de l'hépatite b
PL2981536T3 (pl) 2013-04-03 2017-11-30 Janssen Sciences Ireland Uc Pochodne N-fenylo-karboksyamidu i ich zastosowanie jako leku do leczenia wirusowego zapalenia wątroby typu B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
PL2997019T3 (pl) 2013-05-17 2019-03-29 Janssen Sciences Ireland Uc Pochodne sulfamoilotiofenamidu i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9567299B2 (en) 2013-10-23 2017-02-14 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2702109C1 (ru) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Комбинированная терапия для лечения инфекций вгв
TW201620893A (zh) 2014-02-06 2016-06-16 健生科學愛爾蘭無限公司 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
WO2016004066A1 (fr) * 2014-06-30 2016-01-07 The Uab Research Foundation Nouveaux composés rexinoïde et procédés d'utilisation de composés rexinoïde pour le traitement de troubles métaboliques et du cancer
AU2016232801A1 (en) 2015-03-19 2017-10-12 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10077239B2 (en) 2015-09-29 2018-09-18 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
EP3442524A2 (fr) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Associations et méthodes comprenant un inhibiteur d'ensemble capside
MX2020009531A (es) 2018-03-14 2020-10-05 Janssen Sciences Ireland Unlimited Co Regimen posologico del modulador del ensamblaje de la capside.
EP3810085A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
KR20220005549A (ko) 2019-05-06 2022-01-13 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유도성 질환의 치료에 유용한 아미드 유도체
WO2022162164A1 (fr) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Procedes d'évaluation du risque de développement d'une leuco-entéphalopathie multifocale progressive chez les patients traités par des antagonistes de la vla-4

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5294713A (en) 1991-08-23 1994-03-15 Takeda Chemical Industries, Ltd. 2-piperazinone compounds and their use
WO1995015973A1 (fr) 1993-12-06 1995-06-15 Cytel Corporation Peptidomimetiques cs-1, compositions et procedes pour les utiliser
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU2958195A (en) 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
ATE237342T1 (de) 1994-07-11 2003-05-15 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
WO1996040781A1 (fr) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
JPH11508583A (ja) 1995-07-06 1999-07-27 ゼネカ・リミテッド ペプチド系のフィブロネクチン阻害薬
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
ES2271971T3 (es) * 1996-07-25 2007-04-16 Biogen Idec Ma Inc. Inhibidores de la adhesion celular.
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998042656A1 (fr) 1997-03-21 1998-10-01 Cytel Corporation Nouveaux composes
CA2291778A1 (fr) 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
JP2001517245A (ja) 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
AU728435B2 (en) 1997-05-29 2001-01-11 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6093696A (en) 1997-05-30 2000-07-25 Celltech Therapeutics, Limited Tyrosine derivatives
WO1998058902A1 (fr) 1997-06-23 1998-12-30 Tanabe Seiyaku Co., Ltd. INHIBITEURS D'ADHERENCE CELLULAIRE INDUITE PAR α4β¿1?
AU756696B2 (en) 1997-07-31 2003-01-23 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
EP0994895A1 (fr) 1997-07-31 2000-04-26 Elan Pharmaceuticals, Inc. Composes de dipeptides inhibant une adhesion de leucocytes regulee par vla-4
KR20010022414A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물
BR9811569A (pt) 1997-07-31 2000-09-19 Elan Pharm Inc Compostos que inibem a adesão de leucócito mediada por vla-4
PL338373A1 (en) 1997-07-31 2000-10-23 Elan Pharm Inc Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
AU8823498A (en) 1997-07-31 1999-02-22 American Home Products Corporation Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
EP1001975A1 (fr) 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Composes de benzyle inhibant une adhesion de leucocytes regulee par vla-4
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
HU229362B1 (en) 1997-08-22 2013-11-28 Hoffmann La Roche N-alkanoylphenylalanine derivatives
JP3727536B2 (ja) 1997-08-22 2005-12-14 エフ．ホフマン−ラ ロシュ アーゲー Ｎ−アルカノイルフェニルアラニン誘導体
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU1361499A (en) 1997-10-21 1999-05-10 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
ATE337298T1 (de) * 1997-10-31 2006-09-15 Aventis Pharma Ltd Substituierte anilide
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
WO1999025685A1 (fr) * 1997-11-18 1999-05-27 Merck & Co., Inc. Derives de 4-piperidine carboxamides 4-substitues
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
AU1411499A (en) 1997-11-20 1999-06-15 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
AU1463499A (en) 1997-11-21 1999-06-15 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
AU751950B2 (en) 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
JP2001523711A (ja) 1997-11-24 2001-11-27 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害薬としての環状アミノ酸誘導体
ES2235383T3 (es) * 1997-12-23 2005-07-01 Aventis Pharma Limited Beta-alaninas sustituidas.
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
IL137329A0 (en) * 1998-01-23 2001-07-24 Novartis Ag Vla-4 antagonists
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AU3260399A (en) 1998-02-26 1999-09-15 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
CA2328990C (fr) 1998-04-16 2011-01-11 Texas Biotechnology Corporation Amides n,n-disubstitutes inhibant la fixation d'integrines a leurs recepteurs
WO1999054321A1 (fr) 1998-04-21 1999-10-28 Aventis Pharma Limited Diamines substituees et leur utilisation en tant qu'inhibiteurs d'adhesion cellulaire
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
WO1999061421A1 (fr) 1998-05-28 1999-12-02 Biogen, Inc. L'oMePUPA-V, NOUVEL INHIBITEUR DU VLA-4
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
WO1999064395A1 (fr) 1998-06-11 1999-12-16 Merck & Co., Inc. Composes d'amide heterocycliques utilises comme inhibiteurs d'adhesion cellulaire
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
NZ508033A (en) * 1998-06-30 2002-12-20 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
AU1915399A (en) 1998-07-10 2000-02-01 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
AU5052199A (en) 1998-07-23 2000-02-14 Astrazeneca Ab Chemical compounds
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
EP1114028B1 (fr) 1998-08-26 2006-11-29 Aventis Pharma Limited Bicycles aza modulant l'inhibition de l'adhesion cellulaire
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9821406D0 (en) 1998-10-01 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
WO2000035855A1 (fr) 1998-12-14 2000-06-22 American Home Products Corporation Derives de 3,4-diamino-3-cyclobutene-1,2-dione presentant une adherence aux leucocytes ayant pour origine vla-4
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
WO2000043369A1 (fr) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Composes inhibant l'adhesion aux leucocytes a mediation assuree par vla-4
JP2002535316A (ja) 1999-01-22 2002-10-22 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４により媒介される白血球接着を阻害する縮合環へテロアリールおよび複素環式化合物
WO2000043354A2 (fr) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Composes inhibant l'adhesion leucocytaire provoquee par vla-4
WO2001051487A1 (fr) * 1999-12-28 2001-07-19 Pfizer Products Inc. Inhibiteurs non peptidyle de liaison cellulaire dependant de vla-4 utiles pour le traitement de maladies inflammatoires, auto-immunes et respiratoires

Also Published As

Publication number Publication date
ZA200205142B (en) 2003-09-29
EA004673B1 (ru) 2004-06-24
US6667331B2 (en) 2003-12-23
UY26512A1 (es) 2001-07-31
TR200201668T2 (tr) 2002-11-21
PE20010987A1 (es) 2001-10-02
WO2001051487A1 (fr) 2001-07-19
US20030100585A1 (en) 2003-05-29
GT200000226A (es) 2002-06-20
CO5261616A1 (es) 2003-03-31
JP2003519697A (ja) 2003-06-24
HUP0203897A3 (en) 2005-06-28
CN1413210A (zh) 2003-04-23
AP2002002565A0 (en) 2002-06-30
NO20023085D0 (no) 2002-06-26
CR6682A (es) 2004-01-14
AU2018301A (en) 2001-07-24
PA8509301A1 (es) 2002-12-11
US20020049236A1 (en) 2002-04-25
US6668527B2 (en) 2003-12-30
CA2396087A1 (fr) 2001-07-19
US6903128B2 (en) 2005-06-07
HUP0203897A2 (hu) 2003-03-28
SV2002000246A (es) 2002-07-16
KR20020067050A (ko) 2002-08-21
EA200200619A1 (ru) 2002-10-31
US20040102496A1 (en) 2004-05-27
NZ518886A (en) 2004-02-27
PL357109A1 (en) 2004-07-12
IS6382A (is) 2002-05-14
OA12126A (en) 2006-05-05
TNSN00256A1 (fr) 2002-05-30
BG106867A (en) 2003-02-28
EE200200372A (et) 2003-12-15
NO20023085L (no) 2002-06-26
US20030004196A1 (en) 2003-01-02
YU41202A (sh) 2005-03-15
IL149758A0 (en) 2002-11-10
AR029216A1 (es) 2003-06-18
EP1244656A1 (fr) 2002-10-02
BR0016818A (pt) 2002-10-01
CZ20022072A3 (cs) 2003-05-14
SK8692002A3 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
HUP9903885A2 (hu) 1-Benzil-3-(szubsztituált-heteroaril)-kondenzált pirazolszármazékok alkalmazása a szív- és keringési rendszer, és a központi idegrendszer egyes betegségei kezelésére
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
HUP0301625A2 (hu) Réztartalmú amin-oxidáz inhibitor hatású 1,3,4-oxadiazin-vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MXPA03005464A (es) Agentes antivirales.
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
MY146669A (en) Pyrazole derivatives for treating hiv
HUP0102471A2 (hu) 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HUP0401984A2 (hu) A 4. tipusú foszfodiészteráz enzim aktivitását gátló inhibitorok alkalmazása gyógyszerkészítmények előállítására és más hatóanyagokkal alkotott kombinációik
MA27095A1 (fr) Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer
CY2466B1 (en) Phenyl dihydrobenzofuranes.
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
TR199700878T1 (xx) Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar.
CY2462B1 (en) Cyclohexyl dihydrobenzofuranes.
CA2238875A1 (fr) Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv
SE9903894D0 (sv) Novel compounds
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
DE60318874D1 (en) Pyrazolderivate
EP1019047A4 (fr) Agents antithrombotiques
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto